Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of WSD0922-FU in advanced non-small cell lung cancer
CTR20243106Phase 2Active
- Sponsor
- Versantus
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WSD-0922 in non-small cell lung cancer (NSCLC), sponsored by Versantus. Started Sep 2024; status: active.
02
Drugs
WSD-0922
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243106.